Noon M A, Hess C E
South Med J. 1976 Sep;69(9):1157-60.
Survival and response to chemotherapy were evaluated in 84 adults with granulocytic leukemia (AGL) and 22 with acute lymphocytic leukemia (ALL). Twenty-two of the 84 patients with AGL reveived no chemotherapy (untreated group). The median survival for patients with AGL who achieved complete remission (CR) was 17.1 months, compared to 6.5 months for those who achieved partial remission (PR (p less than 0.05), 2.8 months for those who failed chemotherapy (p less than 0.01), and 2.1 months for the untreated group (p less than 0.01). The median survival for patients with ALL who achieved a CR was 18.2 months, compared to 7.3 months for those who achieved a PR and 7.0 months for those who failed chemotherapy. Of patients with AGL who reveived an adequate trial of chemotherapy, 43% achieved a CR and 16% a PR; 75% of patients with ALL achieved a CR and 13% a PR. Improved survival depends on the induction of a complete or partial remission with the use of aggressive chemotherapy.
对84例成人粒细胞白血病（AGL）患者和22例急性淋巴细胞白血病（ALL）患者的生存情况及化疗反应进行了评估。84例AGL患者中有22例未接受化疗（未治疗组）。达到完全缓解（CR）的AGL患者的中位生存期为17.1个月，达到部分缓解（PR）的患者为6.5个月（p<0.05），化疗失败的患者为2.8个月（p<0.01），未治疗组为2.1个月（p<0.01）。达到CR的ALL患者的中位生存期为18.2个月，达到PR的患者为7.3个月，化疗失败的患者为7.0个月。在接受充分化疗试验的AGL患者中，43%达到CR，16%达到PR；75%的ALL患者达到CR，13%达到PR。生存改善取决于使用积极化疗诱导完全或部分缓解。
